Genzyme's Renvela receives positive opinion in EU for hyperphosphataemia
This article was originally published in Scrip
Executive Summary
The EU's CHMP has issued a positive opinion for Genzyme's Renvela (sevelamer carbonate) 800mg tablet, and 1.6 and 2.4g powder for oral suspension, for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus >1.78 mmol/l.